Using brain stimulation and a nutritional supplement to lower heart disease risk in post-COVID patients
High-Definition Transcranial Direct Current Stimulation (Hd-Tdcs) and Chlorella Pyrenoidosa as an Adjuvant Treatment to Reduce Cardiovascular Risk in Patients With Long COVID
This study is testing if a combination of brain stimulation and a nutritional supplement can help adults and older people who have had COVID-19 lower their risk of heart disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Federal University of Paraíba Academic / other |
| Locations | 1 site (João Pessoa, Paraíba) |
| Trial ID | NCT06255600 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of high-definition transcranial direct current stimulation (HD-tDCS) combined with Chlorella Pyrenoidosa on patients at risk of cardiovascular disease following COVID-19. The study involves adults and elderly participants who have experienced post-COVID symptoms and are at risk for cardiovascular complications. Participants will be randomly assigned to receive either the HD-tDCS treatment and Chlorella or a placebo, with treatment sessions occurring twice a week for five weeks. The trial aims to monitor cardiovascular health and assess the efficacy of these interventions in reducing risks associated with long COVID.
Who should consider this trial
Good fit: Ideal candidates are adults and elderly individuals aged 18 to 80 who have cardiovascular risk and post-COVID symptoms.
Not a fit: Patients with neuromuscular or cognitive instability, pregnancy, or contraindications for neurostimulation or Chlorella use may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce cardiovascular risks in patients recovering from COVID-19.
How similar studies have performed: While the combination of HD-tDCS and nutritional supplements is innovative, similar studies have shown promise in using neurostimulation for various health conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with cardiovascular diagnosis or risk; * Adults and elderly people (18 to 80 years old); * Able to respond to commands and grant consent to participate in the research through the informed consent form; * Who have post-COVID symptoms. Exclusion Criteria: * Patients with a clinical history of neuromuscular or cognitive instability, pregnancy and contraindications for receiving neurostimulation (such as cardiac pacemakers and metallic brain implants); * Patients with contraindications to the use of Chlorella (gastritis, esophagitis, peptic ulcers), * Pregnant patients, patients with stroke and tumors
Where this trial is running
João Pessoa, Paraíba
- Vanessa Meira Cintra — João Pessoa, Paraíba, Brazil (Recruiting)
Study contacts
- Study coordinator: Suellen Andrade, PhD
- Email: suellenandrade@gmail.com
- Phone: +55(83)986046032
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.